187 related articles for article (PubMed ID: 31287604)
1. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
[TBL] [Abstract][Full Text] [Related]
2. Association of disease duration and PASI response rates at week 12 in patients with moderate-to-severe plaque psoriasis receiving biologics in the real-world psoriasis study of health outcomes (PSoHO).
Pinter A; Eyerich K; Costanzo A; Garrelts A; Schuster C; Mert C; Lampropoulou A; Fotiou K; Maul JT; Papp KA
J Dermatolog Treat; 2024 Dec; 35(1):2350227. PubMed ID: 38797734
[TBL] [Abstract][Full Text] [Related]
3. Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort study.
Hansen RL; Jørgensen TS; Egeberg A; Rosenø NAL; Skougaard M; Stisen ZR; Dreyer L; Kristensen LE
Rheumatology (Oxford); 2024 May; 63(6):1593-1598. PubMed ID: 37647648
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of persistence and remission with guselkumab
Zhdanava M; Fitzgerald T; Pilon D; Teneralli RE; Shah A; Diaz L; Lefebvre P; Feldman SR
J Dermatolog Treat; 2024 Dec; 35(1):2349658. PubMed ID: 38747375
[No Abstract] [Full Text] [Related]
5. The efficacy of ixekizumab treatment in Chinese psoriasis patients: a short-term retrospective study.
Yao X; Yuan J; Zhang Y; Li Y
Eur J Dermatol; 2024 Apr; 34(2):176-181. PubMed ID: 38907548
[TBL] [Abstract][Full Text] [Related]
6. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
Mastorino L; Dapavo P; Susca S; Cariti C; Siliquini N; Verrone A; Stroppiana E; Ortoncelli M; Quaglino P; Ribero S
J Dtsch Dermatol Ges; 2024 Jan; 22(1):34-42. PubMed ID: 37926830
[TBL] [Abstract][Full Text] [Related]
7. The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study.
Li Y; Dang L; Lv C; Lin B; Tao J; Yu N; Deng Y; Wang H; Kang X; Qin H; Chen R; Li J; Liang Y; Liang Y; Shi Y
Drug Saf; 2024 Jul; 47(7):711-719. PubMed ID: 38689136
[TBL] [Abstract][Full Text] [Related]
8. Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis.
Thomas SE; Barenbrug L; Hannink G; Seyger MMB; de Jong EMGJ; van den Reek JMPA
Drugs; 2024 May; 84(5):565-578. PubMed ID: 38630365
[TBL] [Abstract][Full Text] [Related]
9. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry.
Lebwohl M; Strober B; Schrader A; Li AH; Eckmann T; Zhu B; Malatestinic WN; Birt J; Feely M; Blauvelt A
Drugs Real World Outcomes; 2024 Jun; ():. PubMed ID: 38914857
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study-IL PSO (Italian Landscape Psoriasis).
Valenti M; Gargiulo L; Ibba L; Malagoli P; Amoruso F; Balato A; Bardazzi F; Burlando M; Carrera CG; Dapavo P; Dini V; Gaiani FM; Girolomoni G; Guarneri C; Lasagni C; Loconsole F; Marzano AV; Maurelli M; Megna M; Orsini D; Travaglini M; Costanzo A; Narcisi A
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1649-1657. PubMed ID: 38748344
[TBL] [Abstract][Full Text] [Related]
11. Ixekizumab-induced urticaria is associated with the short duration of remission in psoriasis by activation of mast cells.
Zhang L; Li X; Xu X; Le Y; Cao H; Zhang J; Xue F; Hu M; Xia Y; Pan M; Chen L; Zheng J
J Am Acad Dermatol; 2024 May; 90(5):970-976. PubMed ID: 38244613
[TBL] [Abstract][Full Text] [Related]
12. Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.
Rompoti N; Stefanaki I; Panagakis P; Vavouli C; Politou M; Papoutsaki M; Befon A; Koutsa F; Lazou E; Koumprentziotis IA; Chasapi V; Stratigos A; Nicolaidou E
Arch Dermatol Res; 2024 Apr; 316(5):133. PubMed ID: 38662223
[TBL] [Abstract][Full Text] [Related]
13. Local injection of micro-dose guselkumab for palmoplantar pustulosis after partial failure of systemic ixekizumab treatment.
Zhou C; Chen D; Diao Z; Wang Y; Hou Y; Yin Z
Australas J Dermatol; 2024 May; 65(3):e75-e76. PubMed ID: 38439213
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of anti-interleukin-17A biological agents for palmoplantar psoriasis and palmoplantar pustulosis: A network meta-analysis.
Xia R; Diao Z; Chen D; Wang Y; Zhou C; Gao Y; Yin Z
Int Immunopharmacol; 2024 Mar; 130():111716. PubMed ID: 38417367
[TBL] [Abstract][Full Text] [Related]
15. Deep resolution of clinical, cellular, and transcriptomic inflammatory markers during 52 weeks of IL-17A inhibition by secukinumab.
Tomalin LE; Kolbinger F; Suprun M; Wharton KA; Hartmann N; Peters T; Glueck A; Milutinovic M; Krueger JG; Suárez-Fariñas M
Clin Exp Dermatol; 2024 Jan; ():. PubMed ID: 38240024
[TBL] [Abstract][Full Text] [Related]
16. Rapid and sustained resolution in generalized pustular psoriasis with IL-17A inhibitors required high adherence: a 96-week analysis in a real-life setting.
Hu K; Liu Y; Liu Y; Jian L; Duan Y; Liu R; Zhang H; Chen J; Zhang M; Kuang Y
Int J Dermatol; 2024 Apr; ():. PubMed ID: 38632699
[TBL] [Abstract][Full Text] [Related]
17. Comparison between super-responders and non-super-responders in psoriasis under adalimumab treatment: a real-life cohort study on the effectiveness and drug survival over one-year.
Liu Y; Hu K; Jian L; Duan Y; Zhang M; Kuang Y
J Dermatolog Treat; 2024 Dec; 35(1):2331782. PubMed ID: 38513258
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO).
Pinter A; Costanzo A; Khattri S; Smith SD; Carrascosa JM; Tada Y; Riedl E; Reich A; Brnabic A; Haustrup N; Lampropoulou A; Lipkovich I; Kadziola Z; Paul C; Schuster C
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1479-1493. PubMed ID: 38113010
[TBL] [Abstract][Full Text] [Related]
19. Risk of multiple sclerosis in patients with psoriasis receiving anti-IL-17 agents: A case-based review.
Tsiogkas SG; Tsimourtou V; Chaidaki K; Dardiotis E; Roussaki-Schulze AV; Bogdanos DP; Zafiriou E
J Dermatol; 2024 Jun; 51(6):844-848. PubMed ID: 38345289
[TBL] [Abstract][Full Text] [Related]
20. Colitis induced by IL-17A-inhibitors.
Grümme L; Dombret S; Knösel T; Skapenko A; Schulze-Koops H
Clin J Gastroenterol; 2024 Apr; 17(2):263-270. PubMed ID: 38060157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
